NatWest Group’s PDL BioPharma, Inc. PDLI Stock Holding History

NatWest Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-91,069	Closed	-$458K	–	402
2015 Q3	$458K	Buy	+91,069	New	+$522K	0.01%	291
2015 Q2	–	Sell	-91,069	Closed	-$641K	–	459
2015 Q1	$641K	Buy	91,069 +20,444	+29%	+$148K	0.01%	283
2014 Q4	$545K	Buy	70,625 +34,420	+95%	+$272K	﹤0.01%	299
2014 Q3	$270K	Hold	36,205	–	–	﹤0.01%	450
2014 Q2	$350K	Sell	36,205 -9,788	-21%	-$87.2K	0.01%	410
2014 Q1	$382K	Sell	45,993 -1,536	-3%	-$13.2K	0.02%	380
2013 Q4	$401K	Sell	47,529 -16,514	-26%	-$139K	0.01%	605
2013 Q3	$510K	Buy	64,043 +5,117	+9%	+$41.1K	0.01%	704
2013 Q2	$455K	Buy	+58,926	New	+$459K	0.01%	616

Other funds holding PDLI

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GAM

Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

NatWest Group's PDLI Position: Q4 2015 in Review

NatWest Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2015, closing a stake of 91,069 shares — an estimated $458K sold.

NatWest Group first reported a position in PDLI in Q2 2013 and held it in 9 quarters. The position peaked at $641K in Q1 2015. 204 funds tracked by Wall St. Rank hold PDLI as of Q4 2015.

NatWest Group reported no remaining PDL BioPharma, Inc. position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 91,069 PDL BioPharma, Inc. shares in Q4 2015, an estimated $458K.
NatWest Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 9 quarters.
NatWest Group's PDL BioPharma, Inc. position peaked at $641K in Q1 2015.
204 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.